TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Salix Pharma Continues to Rise in Anticipation of FDA Decision Shares of Salix Pharmaceuticals (NASDAQ:SLXP) have been rising in anticipation of their upcoming FDA decision, which is due this coming week.Shares for the company rose as much as 34% since July and on September 11, the FDA is scheduled to decide whether or not to approve the company's Metozolv (metoclopramide) Orally Disintegrating Tablets indicated for the short-term treatment of adults with gastroesophageal reflux and for the relief of symptoms associated with diabetic gastroparesis.Complete Story » seekingalpha.com |
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers On Friday, Spectrum Pharmaceuticals (SPPI) announced the company sold $50 million worth of common shares at $7.55. As is often the case when a company sells additional shares, the share price fell.Shares of SPPI closed down -4.39% to $7.18 in Friday trading.Complete Story » seekingalpha.com |
Hospitals See Benefits of eICUs With critical-care specialists in short supply, remote monitoring offers a high-tech solution to the vexing problem facing a growing number of hospitals. online.wsj.com |
Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck Derek Lowe submits: Over the weekend, the results in a small cardiovascular trial came out that compared Merck's (MRK) Zetia (ezetimibe/simvastatin) against Abbott's (ABT) Niaspan (time-release niacin). Niacin's an under-appreciated therapy in the field - it has tolerability problems, mainly irritating and uncomfortable hot flushing, but it really does seem to help normalize lipid numbers. (And that's why Merck itself, among others, have taken cracks at the market). This latest trial was a small one, but people have been starved for data on Zetia ever since it took a surprising hit (in the ENHANCE trial) suggesting that it might not be very efficacious. There's an ongoing larger trial that should answer this question once and for all, but those numbers won't be showing up for another two years. For now, anything that can help clarify what's going on is of great interest to Merck, its investors, and to cardiologists and their patients.Complete Story » seekingalpha.com |
Illumina Unveils System to Cut Genome Sequencing Costs Illumina unveiled technology it says can sequence a person's entire genetic code for under $10,000, a new milestone in the race to improve genetic sequencing. online.wsj.com |